dual agonist glp 1 glucagon Schematic illustration of monoagonists, agonists and triple The clinically most relevant mechanisms

IGF-1 LR3 (Long Arginine 3-IGF-1) is a synthetic protein and lengthened analogue of human insulin-like growth factor-1

Almost all injection contain same ingredients which differ only based upon the intended therapeutic effect such as active ingredients

Skibicka et al., 2011

Children's requirements are lower and increase with age: infants aged 0-6 months have a safe intake of about 0.3 g daily, those aged 712 months need 0.4 g daily, children aged 13 years require 0.5 g, those aged 46 years need 0.8 g, and children aged 710 years should receive 1.0 g daily

Side effects may include injection site reactions, headache, or flushing